AI Trends

Isomorphic Labs Completes $5 Billion Funding Round, Its Second in Six Months

The DecoderUpdated Nov 17 23:37

AI summary

Isomorphic Labs, the Alphabet-owned AI drug discovery company, has completed a $5 billion funding round co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz joining as a new investor and Alphabet and all existing investors participating. This is the company's second major funding round within six months, following a $2.1 billion raise in May 2026. The funds will be used to advance its proprietary IsoDDE (Isomorphic Drug Design Engine) platform and push its drug pipeline into clinical trials; the company says IsoDDE builds on AlphaFold 3 to further predict drug binding and docking sites. Isomorphic Labs was founded in 2021 and has partnerships with Novartis, Eli Lilly, and Johnson & Johnson, and currently has no approved drugs.

Why read this

AI score 72

Isomorphic Labs Raises Another $5 Billion Within Six Months, Funds to Advance IsoDDE Platform and Drug Pipeline into Clinical Trials

Topics

Tags

Body

Alphabet's AI drug discovery company Isomorphic Labs has raised $5 billion, its second billion-dollar round in six months. Greenoaks and Sequoia Capital co-led the round, joined by new backer Andreessen Horowitz along with Alphabet and all existing investors.

The company had already raised $2.1 billion back in May 2026. The money will go toward advancing its in-house platform IsoDDE (Isomorphic Drug Design Engine) and pushing its drug pipeline toward clinical trials. IsoDDE goes beyond AlphaFold 3, according to the company founded in 2021, and aims to better predict drug binding and docking sites. Isomorphic Labs works with Novartis, Eli Lilly, and Johnson & Johnson but has no approved drug to show for it yet.

The company is led by Demis Hassabis, who stepped down from day-to-day leadership of Google Deepmind in August 2026 and now serves as Alphabet's Chief Scientist. Hassabis won the 2024 Nobel Prize in Chemistry alongside John Jumper for their work on AlphaFold.

Deepmind's original AlphaFold team was disbanded in July 2026 . Many researchers moved to Isomorphic Labs or were reassigned to other projects. Nearly a quarter left Deepmind entirely. Deepmind still shipped AlphaGenome 2 in early November 2026, which predicts how DNA variants affect gene activity in specific cell types.

Source

The Decoder